SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

BMO Capital Maintains Outperform on Halozyme Therapeutics, Raises Price Target to $35

BMO Capital maintains Halozyme Therapeutics (NASDAQ:HALO) with a Outperform and raises the price target from $27 to $35.

Benzinga · 05/12/2020 14:36

BMO Capital maintains Halozyme Therapeutics (NASDAQ:HALO) with a Outperform and raises the price target from $27 to $35.